Vitamin D levels in Swiss breast cancer survivors.

BACKGROUND Cholecalciferol (vitamin D3) is widely supplemented in breast cancer survivors because of the role of vitamin D in multiple health outcomes. METHODS We conducted an observational study in 332 women in Eastern Switzerland with early, i.e., nonmetastatic breast cancer. Tumour-, patient-related and sociodemographic variables were recorded. Cholecalciferol intake and serum 25-hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D (1,25(OH)2D) levels were measured at the first visit (baseline) and during a follow-up visit in a median of 210 days (range 87-857) after the first visit. Patients presenting 25(OH)D deficiency were advised to take cholecalciferol supplementation. RESULTS At baseline, 60 (18%) patients had 25(OH)D deficiency (≤50 nmol/l, ≤20 ng/l), and 70 (21%) had insufficiency (50-74 nmol/l, 20-29 ng/l). Out of 121 patients with ongoing cholecalciferol supplementation at baseline, 25(OH)D deficiency and insufficiency was observed in 9 (7%) and 16 (13%) patients, respectively, whereas out of 52 patients with no supplementation, 15 (29%) had deficiency and 19 (37%) had insufficiency. Only 85 (26%) patients had optimal 25(OH)D levels (75-100 nmol/l, 30-40 ng/l) at baseline. Seasonal variation was significant for 25(OH)D (p = 0.042) and 1,25(OH)2D (p = 0.001) levels. Living in a rural area was associated with a higher median 25(OH)D concentration as compared with living in an urban area (87 nmol/l, range 16-216 vs 72 nmol/l, range 17-162; p = 0.001). Regular sporting activity was positively associated with 25(OH)D (p = 0.045). Body mass index was inversely related to both 25(OH)D and 1,25(OH)2D (Spearman's rho = -0.24, p <0.001; rho = -0.23, p <0.001, respectively). The levels of 25(OH)D and 1,25(OH)2D were correlated (rho = 0.21, p <0.001). Age and bone mineral density had no significant correlation with the levels of 25(OH)D. Follow-up 25(OH)D was available for 230 patients, 44 (19%) of whom had 25(OH)D deficiency and 47 (21%) had insufficiency; 25 (41.6%) initially 25(OH)D-deficient patients attained sufficient 25(OH)D levels, whereas 33 (16.5%) patients with sufficient baseline 25(OH)D levels became deficient. Only 67 (30%) patients presented optimal 25(OH)D at the follow-up. CONCLUSION A remarkable fraction of the patients had serum 25(OH)D below (40%) or above (30%) optimal levels, and only around 30% of patients had optimal levels. Levels of 25(OH)D and 1,25(OH)2D increased on cholecalciferol supplementation, but the usual supplementation regimens were not adequate to bring 25(OH)D to the optimal range for a large proportion of patients. TRIAL REGISTRATION NUMBER EKSG 08/082/2B.

[1]  S. Wimalawansa.  Non-musculoskeletal benefits of vitamin D , 2018, The Journal of Steroid Biochemistry and Molecular Biology.

[2]  Song Liu,et al.  Association of Serum Level of Vitamin D at Diagnosis With Breast Cancer Survival: A Case-Cohort Analysis in the Pathways Study , 2017, JAMA oncology.

[3]  D. Kiel,et al.  Vitamin D, bones and muscle: myth versus reality , 2017, Australasian journal on ageing.

[4]  David A. Jolliffe,et al.  Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data , 2017, British Medical Journal.

[5]  H. Weiler,et al.  The C-3α Epimer of 25-Hydroxycholecalciferol from Endogenous and Exogenous Sources Supports Normal Growth and Bone Mineral Density in Weanling Rats. , 2017, The Journal of nutrition.

[6]  P. Dhawan,et al.  Vitamin D, calcium homeostasis and aging , 2016, Bone Research.

[7]  Discrepant association of serum C-3 epimer of 25-hydroxyvitamin D versus non-epimeric 25-hydroxyvitamin D with serum lipid levels , 2016, Lipids in Health and Disease.

[8]  Predicted 25-hydroxyvitamin D in relation to incidence of breast cancer in a large cohort of African American women , 2016, Breast Cancer Research.

[9]  W. Muller,et al.  Tumoral Vitamin D Synthesis by CYP27B1 1-α-Hydroxylase Delays Mammary Tumor Progression in the PyMT-MMTV Mouse Model and Its Action Involves NF-κB Modulation. , 2016, Endocrinology.

[10]  M. Touvier,et al.  Weight Status and Alcohol Intake Modify the Association between Vitamin D and Breast Cancer Risk. , 2016, The Journal of nutrition.

[11]  M. Zylberman,et al.  Vitamin D deficiency in patients admitted to the general ward with breast, lung, and colorectal cancer in Buenos Aires, Argentina , 2016, Archives of Osteoporosis.

[12]  M. Touvier,et al.  Prospective associations between vitamin D status, vitamin D-related gene polymorphisms, and risk of tobacco-related cancers. , 2015, The American journal of clinical nutrition.

[13]  A. Tjønneland,et al.  A Reverse J-Shaped Association Between Serum 25-Hydroxyvitamin D and Cardiovascular Disease Mortality: The CopD Study. , 2015, The Journal of clinical endocrinology and metabolism.

[14]  Xulei Tang,et al.  High prevalence of vitamin D deficiency among middle-aged and elderly individuals in northwestern China: its relationship to osteoporosis and lifestyle factors. , 2015, Bone.

[15]  G. Salles,et al.  Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Prentice,et al.  25(OH)D2 Half-Life Is Shorter Than 25(OH)D3 Half-Life and Is Influenced by DBP Concentration and Genotype , 2014, The Journal of clinical endocrinology and metabolism.

[17]  E. Giovannucci,et al.  The role of vitamin D in reducing cancer risk and progression , 2014, Nature Reviews Cancer.

[18]  P. Autier,et al.  Vitamin D status and ill health--author's reply. , 2014, The lancet. Diabetes & endocrinology.

[19]  S. Mohr,et al.  Meta-analysis of vitamin D sufficiency for improving survival of patients with breast cancer. , 2014, Anticancer research.

[20]  J. Knight,et al.  An Integrated Approach to Defining Genetic and Environmental Determinants for Major Clinical Outcomes Involving Vitamin D , 2014, Molecular Diagnosis & Therapy.

[21]  K. Yasuda,et al.  CYP24A1 as a potential target for cancer therapy. , 2014, Anti-cancer agents in medicinal chemistry.

[22]  S. Gandini,et al.  Vitamin D receptor polymorphisms and cancer. , 2014, Advances in experimental medicine and biology.

[23]  P. Autier,et al.  Vitamin D status and ill health: a systematic review. , 2014, The lancet. Diabetes & endocrinology.

[24]  C. Wagner,et al.  Clinical review: The role of the parent compound vitamin D with respect to metabolism and function: Why clinical dose intervals can affect clinical outcomes. , 2013, The Journal of clinical endocrinology and metabolism.

[25]  J. Malm,et al.  Determinants of serum levels of vitamin D: a study of life-style, menopausal status, dietary intake, serum calcium, and PTH , 2013, BMC Women's Health.

[26]  L. Risch,et al.  Serum concentrations of 25-hydroxyvitamin D and immunoglobulins in an older Swiss cohort: results of the Senior Labor Study , 2013, BMC Medicine.

[27]  M. Holick,et al.  Vitamin D for health: a global perspective. , 2013, Mayo Clinic proceedings.

[28]  D. Eaton,et al.  Enhancement of hepatic 4‐hydroxylation of 25‐hydroxyvitamin D3 through CYP3A4 induction in vitro and in vivo: Implications for drug‐induced osteomalacia , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  S. Bojesen,et al.  Low plasma 25-hydroxyvitamin D and risk of tobacco-related cancer. , 2013, Clinical chemistry.

[30]  H. Brenner,et al.  Serum 25-Hydroxyvitamin D and Cancer Risk in Older Adults: Results from a Large German Prospective Cohort Study , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[31]  B. Skidmore,et al.  Vitamin D: Pharmacokinetics and Safety When Used in Conjunction with the Pharmaceutical Drugs Used in Cancer Patients: A Systematic Review , 2013, Cancers.

[32]  S. Pilz,et al.  Vitamin D supplementation and cancer: review of randomized controlled trials. , 2012, Anti-cancer agents in medicinal chemistry.

[33]  Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors , 2013, BMC Cancer.

[34]  Sabina Rinaldi,et al.  Circulating levels of 25-hydroxyvitamin D and risk of breast cancer: a nested case-control study , 2013, Breast Cancer Research.

[35]  D. Gruson,et al.  The influence of renal function on vitamin D metabolism in the very elderly , 2012, The journal of nutrition, health & aging.

[36]  R. Trawick,et al.  Circulating interferon-γ correlates with 1,25(OH)D and the 1,25(OH)D-to-25(OH)D ratio. , 2012, Cytokine.

[37]  C. Shapiro,et al.  Aromatase Inhibitor-Associated Bone Loss , 2008, Drugs.

[38]  B. Hollis.  Short-term and long-term consequences and concerns regarding valid assessment of vitamin D deficiency: comparison of recent food supplementation and clinical guidance reports , 2011, Current opinion in clinical nutrition and metabolic care.

[39]  A. Petróczi,et al.  Misleading measures in Vitamin D analysis: A novel LC-MS/MS assay to account for epimers and isobars , 2011, Nutrition journal.

[40]  Ziekenhuis Rijnstate.  Cholecalciferol Loading Dose Guideline for Vitamin D deficient Adults , 2010 .

[41]  T. Bruckner,et al.  Are commonly recommended dosages for vitamin D supplementation too low? Vitamin D status and effects of supplementation on serum 25-hydroxyvitamin D levels—an observational study during clinical practice conditions , 2010, Osteoporosis International.

[42]  A. Scillitani,et al.  Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. , 2008, The Journal of clinical endocrinology and metabolism.

[43]  P. Vestergaard,et al.  Plasma 1,25(OH)2D levels decrease in postmenopausal women with hypovitaminosis D. , 2008, European journal of endocrinology.

[44]  R. Recker,et al.  Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. , 2007, The American journal of clinical nutrition.

[45]  R. Vieth.  What is the optimal vitamin D status for health? , 2006, Progress in biophysics and molecular biology.

[46]  Ravinder J. Singh,et al.  C-3 Epimers Can Account for a Significant Proportion of Total Circulating 25-hydroxyvitamin D in Infants, Complicating Accurate Measurement and Interpretation of Vitamin D Status , 2022 .

[47]  W. Willett,et al.  Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. , 2006, The American journal of clinical nutrition.

[48]  W. L. Nelson,et al.  Intestinal and Hepatic CYP3A4 Catalyze Hydroxylation of 1α,25-Dihydroxyvitamin D3: Implications for Drug-Induced Osteomalacia , 2006, Molecular Pharmacology.

[49]  M. Holick,et al.  Analysis of 25-hydroxyvitamin D3-1alpha-hydroxylase in normal and malignant breast tissue. , 2005, Anticancer research.

[50]  D. Malatesta,et al.  Response of bone metabolism related hormones to a single session of strenuous exercise in active elderly subjects , 2005, British Journal of Sports Medicine.

[51]  B. Hollis.  Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. , 2005, The Journal of nutrition.

[52]  Edward Giovannucci,et al.  The epidemiology of vitamin D and cancer incidence and mortality: A review (United States) , 2005, Cancer Causes & Control.

[53]  K. Inouye,et al.  C-3 Epimerization of Vitamin D3 Metabolites and Further Metabolism of C-3 Epimers , 2004, Journal of Biological Chemistry.

[54]  D. Lugg,et al.  Effect of seasonal ultraviolet radiation fluctuations on vitamin D homeostasis during an Antarctic expedition , 2004, European Journal of Applied Physiology and Occupational Physiology.

[55]  G. Bailie,et al.  Comparative Review of the Pharmacokinetics of Vitamin D Analogues , 2002, Seminars in dialysis.

[56]  M. Uskoković,et al.  Differential activities of 1alpha,25-dihydroxy-16-ene-vitamin D(3) analogs and their 3-epimers on human promyelocytic leukemia (HL-60) cell differentiation and apoptosis. , 2001, Steroids.

[57]  G. Miller,et al.  Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  M. Holick,et al.  Quantification and kinetics of 25-hydroxyvitamin D3 by isotope dilution liquid chromatography/thermospray mass spectrometry. , 1993, Biological mass spectrometry.

[59]  T. Kobayashi,et al.  Variation of 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 levels in human plasma obtained from 758 Japanese healthy subjects. , 1983, Journal of nutritional science and vitaminology.

[60]  R. Jung,et al.  Abnormal vitamin D metabolism in cirrhosis. , 1978, Gut.

[61]  J. Dominguez,et al.  The metabolism of vitamin D3 and 25-hydroxyvitamin D3 in normal and anephric humans. , 1974, The Journal of clinical endocrinology and metabolism.

[62]  E. Mawer,et al.  Long Biological Half-life of Vitamin D3 and its Polar Metabolites in Human Serum , 1969, Nature.

[63]  R. Vieth,et al.  Efficacy and safety of vitamin D 3 intake exceeding the lowest observed adverse effect level 1 – 3 , 2022 .